![Behshad Sheldon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Behshad Sheldon
Direktor/Vorstandsmitglied bei
EGETIS THERAPEUTICS AB
Vermögen: 57 022 $ am 31.05.2026
Profil
Behshad Sheldon is the founder of Pocket Naloxone Corp., founded in 2019, serving as Director.
Current jobs include Chairman at Female Opioid Addiction Research & Clinical Experts; Independent Director at Egetis Therapeutics AB since 2023; Executive Vice President & Managing Director at Biotech Value Advisors LLC since 2020; and Director at Maxona Pharmaceuticals, Inc. since 2021.
Former jobs include President, CEO & Executive Director at Braeburn, Inc.; President & Chief Executive Officer at Braeburn Pharmaceuticals SPRL from 2012 to 2017; Independent Director at Avalo Therapeutics, Inc. from 2014 to 2016; Independent Director at Camurus AB from 2018 to 2024; Vice President-Global Marketing at Otsuka Pharmaceutical Development & Commercialization, Inc.; Principal at GlaxoSmithKline LLC; and Venture Partner at Apple Tree Venture Management LLC from 2013 to 2016.
Education includes an undergraduate degree from Rochester Christian University, conferred in 1984.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CAMURUS AB 0 % | 31.12.2024 | 1.000 ( 0 % ) | 57 022 $ | 31.05.2026 |
| 31.12.2025 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Behshad Sheldon
| Unternehmen | Position | Beginn |
|---|---|---|
| EGETIS THERAPEUTICS AB | Direktor/Vorstandsmitglied | 01.01.2023 |
Pocket Naloxone Corp.
 Pocket Naloxone Corp. Medical DistributorsDistribution Services Supplies naloxone medicines | Gründer | 01.01.2019 |
Biotech Value Advisors LLC | Corporate Officer/Principal | 01.01.2020 |
Maxona Pharmaceuticals, Inc.
 Maxona Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that develops therapies to help patients | Direktor/Vorstandsmitglied | 01.10.2021 |
Ehemalige bekannte Positionen von Behshad Sheldon
| Unternehmen | Position | Ende |
|---|---|---|
| CAMURUS AB | Direktor/Vorstandsmitglied | 08.05.2024 |
| BRAEBURN INC. | Vorstandsvorsitzender | 05.06.2017 |
Braeburn Pharmaceuticals SPRL
 Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Develops and commercializes medical products | Vorstandsvorsitzender | 01.01.2017 |
| AVALO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 30.09.2016 |
Apple Tree Venture Management Llc//vc
 Apple Tree Venture Management Llc//vc Investment ManagersFinance Apple Tree Partners invests in companies located in the United States. The firm focuses on the life sciences sector. It provides financing for seed, early and later stage capital requirements. | Private Equity Investor | 01.01.2016 |
Ausbildung von Behshad Sheldon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Rochester Christian University
 Rochester Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Camurus AB
 Camurus AB Pharmaceuticals: MajorHealth Technology Provides nanoscale drug delivery systems for development of high value therapeutics | Health Technology |
Apple Tree Venture Management Llc//vc
Apple Tree Venture Management Llc//vc Investment ManagersFinance Apple Tree Partners invests in companies located in the United States. The firm focuses on the life sciences sector. It provides financing for seed, early and later stage capital requirements. | Finance |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Braeburn Pharmaceuticals SPRL
Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Develops and commercializes medical products | Health Technology |
Braeburn, Inc.
 Braeburn, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and manufactures pharmaceutical products for opioid use disorder | Commercial Services |
Pocket Naloxone Corp.
Pocket Naloxone Corp. Medical DistributorsDistribution Services Supplies naloxone medicines | Distribution Services |
Maxona Pharmaceuticals, Inc.
Maxona Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that develops therapies to help patients | Health Technology |
Biotech Value Advisors LLC |
